Idelle

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Idelle

What is Idelle? Defining the Estriol Preparation

Property Description
Active ingredient Estriol (INN)
Form Cream, Tablet, Insert, Suppository
Pharmacological class Estrogen Medication, Steroid Hormone
Common use Estrogen deficiency conditions
Origin Naturally Occurring, Bioidentical

Idelle is a prescription-only pharmaceutical product whose active substance is Estriol (E₃), placing it within the broad pharmacological class of estrogen medications. It is fundamentally classified as a steroid hormone preparation, designed to act as a single-ingredient product (monotherapy) to supplement the body’s intrinsic estrogen levels. The formulation of Estriol is clinically recognized for its role in localized hormonal support.

Estriol refers to a naturally occurring, bioidentical hormone, meaning its chemical structure is identical to one of the three primary estrogens produced by the human body. Estriol is biologically classified as a weak estrogen because its binding affinity and duration of action at the estrogen receptors are significantly lower than those of Estradiol (E₂). Estriol is used to address symptoms related to hormonal changes, particularly in localized areas, helping to alleviate the physical changes and discomfort caused by low hormone levels.

Available Forms and General Therapeutic Purpose

Preparations containing Estriol, such as Idelle, are typically available in multiple dosage forms, including tablets for oral administration and localized forms such as vaginal creams, inserts, or suppositories. The specific form chosen dictates the primary route of administration, which may be systemic or primarily local, allowing for targeted application. For instance, the vaginal cream form is often positioned specifically for patients requiring localized treatment in the lower urinary and genital tracts.

The general therapeutic purpose of Idelle is to support the structural integrity and functionality of tissues that are dependent on estrogen. By supplying this estrogen, the preparation helps to counter the adverse changes associated with declining hormone levels, thereby providing relief from discomfort related to estrogen deficiency conditions in postmenopausal women.

What side effects are possible with Idelle?

Adverse reaction scope

Key adverse reaction categories: Official regulatory documents, including FDA labeling and EMA summaries, contain strong warnings concerning fatal and serious toxicities, primarily hepatotoxicity (liver damage), severe diarrhea/colitis, pneumonitis (lung inflammation), serious infections, and intestinal perforation.

Frequency Classification System-Organ Classes Involved
Common (ge 20%): Diarrhea, pyrexia (fever), fatigue, nausea, cough, pneumonia, rash, chills. Gastrointestinal, Hepatic, Infections, Respiratory, Hemic and Lymphatic (Neutropenia).

Serious adverse reactions (as documented in regulatory sources): Fatal and/or serious hepatotoxicity, severe diarrhea or colitis, pneumonitis, intestinal perforation, and serious infections, including opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP) and Cytomegalovirus (CMV).

Population-specific safety considerations (if applicable):

  • Embryo-Fetal Toxicity: May cause fetal harm; effective contraception is required during treatment and for a specified time after the final dose (one month for women, three months for men).
  • Hepatic Impairment: Intensified monitoring of adverse reactions is recommended in patients with pre-existing impaired hepatic function.

Safety-related restrictions or limitations: Use is Contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis or toxic epidermal necrolysis, to the active substance. Regular monitoring of liver function tests and blood cell counts is required.


Safety classifications (high-level)

Regulatory frequency framework used: Frequency categories (e.g., Common, Very Common) are based on the incidence rates observed in clinical trials, as defined in official regulatory prescribing information.

Regulatory basis (EMA / FDA / other government authority): Primarily FDA and EMA, which emphasize the risks through prominent warnings, including a regulatory Boxed Warning in U.S. labeling.

Resulting safety structure

  • Regulatory safety documents highlight the risk of organ-specific toxicities, especially affecting the liver and lungs.
  • The profile emphasizes high-frequency gastrointestinal events and the potential for severe, late-onset diarrhea or colitis.
  • A key focus is the necessity of safety monitoring (e.g., blood tests) to detect liver enzyme elevations or severe drops in white blood cell counts (neutropenia).

Connection to the overall safety profile (2–4 sentences): The official safety structure of Idelle (Idelalisib) clearly prioritizes the communication of serious, potentially fatal, systemic toxicities and infections, establishing the medicine's risk profile as one requiring active and frequent monitoring. The profile organizes known adverse reactions by frequency and body system, ensuring that patients and clinicians are fully informed of both common and critical safety elements.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory classification for an acute overdose involving Estriol (Idelle) preparations indicates that serious or life-threatening symptoms are very unlikely to occur. Overdose is primarily associated with an exaggeration of known estrogen effects, which directs the required medical response toward immediate action and supportive care, as dictated by governmental prescribing information.

Documented Manifestations

The most common documented manifestations of an Estriol overdose may include effects on the gastrointestinal, reproductive, and central nervous systems. These presentations include nausea, vomiting, and abdominal pain. Additional documented signs are breast tenderness, fatigue, drowsiness, and the occurrence of withdrawal bleeding (vaginal bleeding), which typically manifests several days following the exposure event.

Required Emergency Actions

Official guidance mandates that if an overdose is suspected, the individual must seek medical help right away. This requires contacting the national Poison Help hotline (1-800-222-1222) or local emergency services, exactly as written in the government guidance. If the individual collapses, has a seizure, or is experiencing difficulty breathing, immediate contact with emergency services (such as 911) is required.

Management Protocol

Regulatory documents state that there is no specific antidote known for an Estriol overdose. Therefore, treatment focuses on providing symptomatic and supportive care. This management includes monitoring the individual's vital signs and administering medications to treat specific symptoms as required, procedures which are documented in the official prescribing information.

Therapeutic Uses of Idelle

Idelle, an Estriol preparation, is commonly used to provide symptomatic and structural support within the therapeutic domain of Estrogen Deficiency Conditions, primarily for postmenopausal women. Estriol is used to help manage vaginal estrogen deficiency symptoms and atrophy.


Therapeutic Focus and Patient Benefit

This treatment is applied in clinical settings that involve chronic, persistent discomforts associated with Vulvovaginal Atrophy (VVA) and Genitourinary Syndrome of Menopause (GSM). It is relevant for easing challenging symptoms, including vaginal dryness, burning, vulvar itching, and Dyspareunia (painful intercourse). Furthermore, it supports the lower urogenital tract in situations where symptoms such as urinary urgency, frequency, and the recurrence of symptomatic episodes are linked to estrogen deficiency. The medication provides supportive relief when these symptoms interfere with routine activities.

“The intent of this supportive treatment is to assist with maintaining functional stability and to help improve day-to-day comfort during symptomatic periods.”

In these contexts, Idelle provides supportive relief during difficult episodes, assisting with maintaining functional stability and helping to manage the overall symptom burden.


Quick Fact: Support for Persistent Vaginal Symptoms Idelle is commonly used when symptoms of vaginal dryness and irritation are persistent and caused by hormonal changes, supporting the patient by helping to ease the overall symptom load.

Eligibility and Restrictions for Use

Idelle is an Estriol preparation whose official use is strictly defined by regulatory eligibility criteria. The medicine is primarily intended for postmenopausal women seeking to address localized symptoms related to estrogen deficiency, such as atrophic vaginitis.

Use is contraindicated (absolutely must not be used) in several population groups. These absolute exclusions include patients with a known, past, or suspected history of breast cancer or other oestrogen-dependent malignant tumours. The medicine is also prohibited for individuals with a history of venous or arterial thromboembolic disease (including DVT, pulmonary embolism, or stroke), as well as those with known thrombophilic disorders.

Further constraints apply to physiological status and organ function. Idelle is strictly contraindicated during pregnancy and is not recommended for women who are breastfeeding. Non-eligibility also extends to patients with acute liver disease or unrecovered liver function abnormalities, undiagnosed genital bleeding, and untreated endometrial hyperplasia. The preparation is not indicated in children and is limited to use in the adult, postmenopausal population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Idelalisib’s interaction profile is characterized by its effect on drug metabolizing enzymes, requiring careful management of concomitant medications.


Interaction Scope

Entity Detail (Official Regulatory Statement)
Medicinal Product Categories Strong/moderate CYP3A substrates (especially those with narrow therapeutic index); Strong CYP3A inducers; Strong CYP3A inhibitors; Other immunosuppressive agents.
Specific Interacting Medicines Contraindicated: Alfuzosin, Astemizole, Dihydroergotamine, Lurasidone, Lovastatin, Simvastatin, Midazolam (oral), Triazolam. Avoided: Strong CYP3A inducers (e.g., Rifampin, St. John's Wort).
Mechanistic Basis Idelalisib's major metabolite is a strong inhibitor of CYP3A4, significantly increasing co-administered substrate exposure. Idelalisib itself is metabolized by aldehyde oxidase and CYP3A4.
Population-Specific Notes Hepatic Impairment: Intensified monitoring is required for patients with impaired hepatic function, as increased drug exposure is expected.

Interaction Restrictions and Classification

Classification Detail (Official Regulatory Statement)
Interaction-Related Restrictions Avoidance of strong CYP3A inducers is mandated due to potential loss of efficacy. Contraindication of certain CYP3A substrates is required to prevent serious toxicity from increased systemic exposure. May reduce the effectiveness of hormonal contraceptives (Ethinyl Estradiol containing products).
Interaction Severity Contraindicated (Specific CYP3A substrates); Avoided (Strong CYP3A inducers); Requires Monitoring/Dose Adjustment (Other CYP3A substrates, strong CYP3A inhibitors).

Official Interaction Statements

  • The primary metabolite strongly inhibits CYP3A4, which significantly increases plasma concentrations of co-administered CYP3A substrates.
  • Co-administration with strong CYP3A inducers is avoided because it substantially decreases Idelalisib plasma concentration and may reduce clinical effectiveness.
  • Concomitant use with other immunosuppressive therapies requires close monitoring due to documented additive risks.

Connection to the Overall Interaction Profile The regulatory documents define the product's interaction structure primarily through its role as a strong CYP3A inhibitor, which imposes definitive restrictions, including absolute contraindications, for co-administration with many narrow therapeutic index drugs. The profile requires strict adherence to avoidance and monitoring protocols for both CYP3A inhibitors and inducers that affect the drug's metabolism.

Mechanism of Action

Nuclear Estrogen Receptor Activation

Idelle's mechanism is initiated by Estriol binding as a partial agonist to the nuclear Estrogen Receptors ( ERalpha and ERbeta). This interaction activates the genomic signaling pathway, driving the transcription of genes associated with cellular proliferation and tissue structure. The molecule's weak agonism and rapid receptor clearance constrain its activity primarily to the local tissue level.

Modulation of Tissue Structure and Local Homeostasis

Resulting genetic signaling promotes the growth and differentiation of epithelial cells, which increases tissue thickness and local vascularity (blood flow) within the affected areas. The mechanism also increases the cellular content of glycogen. This glycogen acts as a substrate for local bacteria, and the subsequent bacterial metabolism converts the glycogen into lactic acid. This process maintains the local acidic pH environment. This sequence of molecular and cellular changes results in fundamental alterations to the tissue structure and local biochemical profile.

Dosage and Administration Information

How Idelle is Used — Administration Guidelines

Idelle (Estriol) is an estrogen preparation strictly intended for localized use via the intravaginal route. This administration method is used because the medicine is formulated to act on specific tissues in the lower urogenital tract. The administration protocol is defined in distinct cycles, which govern the intensity and duration of use.

Standard Dosing Regimens and Schedules

The treatment typically requires a transition from an initial daily course to a long-term maintenance schedule.

Schedule Phase Single Dose Frequency and Duration
Initial Treatment 0.5 mg Estriol (one calibrated dose) Once daily for a period not exceeding 4 weeks.
Maintenance Treatment 0.5 mg Estriol (one calibrated dose) Twice a week (intermittent use).

The daily regimen is also prescribed for specific pre-operative support, lasting 2 weeks immediately prior to scheduled surgery. Following the operation, the twice-weekly maintenance dose is typically resumed approximately 2 weeks post-surgery.

Administration Conditions and Timing

Administration is recommended to occur before going to bed to optimize product retention. The cream formulation requires the use of a calibrated applicator to ensure accurate delivery of the 0.5 mg dose. The same dosing regimen is applied to older adults as no specific dose adjustment is stipulated in the prescribing information for localized use.

Protocol for a Missed Dose

If a scheduled dose is missed, the standard procedure is to administer it immediately, unless the omission is more than 12 hours past the usual time. If more than 12 hours have passed, the missed dose must be skipped. Two doses must never be administered on the same day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Idelle (Estriol)

Evidence for Vulvovaginal Atrophy (VVA) and Genitourinary Syndrome of Menopause (GSM)

The evidence base for Estriol is primarily drawn from short-term, randomized controlled trials (RCTs) that were evaluated in postmenopausal women experiencing VVA and GSM symptoms. These studies explored how symptoms change over time, comparing localized Estriol to a non-active treatment. Systematic reviews synthesize these findings, contributing to the broader evidence landscape.

Studies on Symptom Resolution and Tissue Health

Research explored patient-reported outcomes describing perceived discomfort, such as changes in the intensity of dryness, itching, and pain experienced during intercourse (Dyspareunia). Findings describe patterns observed in the studies with participants who were receiving Estriol, and report how their symptoms evolved. Researchers also monitored objective physiological measures, with data showing patterns related to tissue health, including shifts in the Maturation Index and vaginal acidity.

Evidence for Recurrent Urinary Tract Issues

Studies was studied for outcomes related to the recurrence rate of urinary tract infections (rUTI) that was associated with estrogen deficiency. The research examined the number of rUTI episodes experienced over a typical study period of 6 to 12 months in the studied groups. Evidence quality varies across studies, and comparative evidence is often limited.

Long-term Studies and Durability of Follow-up

The pivotal research was observed in trials with follow-up durations that were limited, mostly covering the first few months to a year. Therefore, long-term effects are not fully established. Regarding specific populations, limited specialized studies was studied for women with certain medical conditions, such as those on aromatase inhibitor treatment, but subgroup findings are uncertain due to modest sample sizes.

Research Gaps and Areas of Uncertainty

The primary limitation is that there is limited information for long-term outcomes that fully track the effects of using localized Estriol beyond one year. Research also continues to explore how different patient groups may respond. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Idelle (FAQ)

Q: How quickly does Idelle start to work?

A: Clinical study observations describe that this medicine acts by promoting gradual changes in the local tissue structure. For this reason, patient-reported symptoms of dryness and discomfort may begin to show patterns of improvement within a few weeks of starting treatment.

Q: What are the general expectations when starting treatment with Idelle?

A: When initiating a new medication, the body commonly goes through an adjustment period. Official information notes that some patients may temporarily experience minor effects, such as local irritation or breast tenderness, which are often described as transient. If any symptom is persistent or concerning, patients are advised to consult with a healthcare provider.

Q: What are the main research findings about Idelle's effectiveness?

A: The official research evidence primarily supports the use of the medicine for relieving localized symptoms associated with estrogen deficiency in postmenopausal women. The findings indicate improvements in symptoms such as dryness, irritation, and pain experienced during intercourse, related to the improved health of the affected tissues.

Q: Is Idelle safe to use long-term?

A: Regulatory documents recommend that the benefits and risks of continued use be reviewed periodically by a healthcare provider, often at least once a year. Long-term follow-up beyond 12 months should be carefully assessed, as some regulatory guidance may recommend time limits on higher-strength hormonal products.

Q: Can people with liver problems take Idelle?

A: Regulatory documents state that this medicine is strictly prohibited (contraindicated) for individuals with acute liver disease or if their liver function has not completely recovered. In official prescribing information, patients with pre-existing liver issues are noted as requiring close supervision by a healthcare provider.

Q: What if I'm taking vitamins — will they interact with Idelle?

A: Official information indicates that because this medicine is designed for local treatment with low systemic absorption, it is generally considered unlikely to affect other medicines or vitamins taken by mouth. However, it remains important to inform your healthcare provider about all products, including vitamins and supplements, that you are using.

Q: What should I do if a side effect is bothersome?

A: If a side effect is bothersome or persistent, or if you notice any potential signs of a more serious problem (like unusual bleeding or swelling), official guidance advises that patients contact a doctor or pharmacist for guidance.

Q: What are the signs that Idelle might be working?

A: Signs that the medicine may be working can be observed through patient-reported improvements, such as reduced dryness and discomfort. Physiologically, official sources describe changes over time that increase tissue thickness and help improve local blood flow.

Q: Does Idelle cause weight gain?

A: Official safety monitoring has generally not linked the use of localized vaginal estrogens to significant weight gain. However, weight changes have been reported as a less common effect in broader studies of hormone therapy.

Q: Is it normal to feel tired when first starting Idelle?

A: Tiredness and fatigue are symptoms that have been noted in association with the use of estrogen-containing medicines in some individuals. Official documents do not explicitly define if this is 'normal' or temporary when a person first begins using the medicine.

Q: Can Idelle be used for conditions other than what it's mainly prescribed for?

A: The medicine is officially approved and indicated only for the treatment of specific symptoms related to estrogen deficiency in postmenopausal women, such as atrophic vaginitis. Official regulatory indications do not support use for other conditions.

Q: Does Idelle affect sleep patterns?

A: Some official post-marketing reports for estrogen-containing medicines have included trouble sleeping or insomnia. However, the exact frequency or a direct link to this specific localized treatment is not always clearly defined in official regulatory documents.

Q: Do many people experience headaches with Idelle?

A: Headache is listed as a common side effect reported in clinical trials and safety surveillance for estrogen-containing medicines. In clinical observations, these effects are sometimes noted to be temporary and may lessen as the body adjusts to the treatment.

Q: Why is Idelle prescribed to people with [Condition name, or general symptoms]?

A: It is prescribed because it contains Estriol, a weak estrogen, which is designed to act locally on tissues that are dependent on estrogen. This action helps to counter the adverse physical and biochemical changes caused by declining hormone levels in postmenopausal women.

Q: Is Idelle generally considered a well-tolerated medicine?

A: Official documents list known side effects, ranging from common local reactions to potential systemic risks. Tolerability is generally described in relation to the medicine's low systemic absorption when used as directed, but individual experience can vary.

Q: How is Idelle eliminated from the body?

A: Official pharmacokinetics data states that Estriol, the active ingredient, is mainly processed and eliminated from the body via the urine. It is typically removed as conjugates, which are forms of the drug combined with other substances.

Q: Does Idelle interact with alcohol?

A: There is no known drug-specific interaction between this local medicine and alcohol listed in official regulatory documents. In general, patients are often advised that normal consumption of food and alcohol can be done while using vaginal estrogen.

Q: Is there any information about Idelle and mood changes?

A: Mood-related symptoms, such as irritability, feeling sad or empty, and mental depression, have been noted in association with estrogen-containing medicines in some official clinical and postmarketing reports.

Q: Are there any restrictions on activities while taking Idelle?

A: Official regulatory documents have not reported any effects on the ability to drive or use machines. Because the medicine is primarily for localized use, no specific restrictions on typical daily activities are usually mandated in the product information.

Q: Does Idelle work immediately or build up over time?

A: The medicine works by activating genetic signals that promote cellular growth and structural changes in the tissues, which is a process that requires time. Therefore, symptom relief is typically a gradual process that develops over a period of several weeks.

Q: What is the source of the research about Idelle?

A: The official evidence base is primarily derived from clinical trials, including short-term randomized controlled trials (RCTs), and systematic reviews of this data. This information is synthesized and reviewed by government authorities to support the medicine's official approvals and indications.

Q: Can Idelle be crushed or split?

A: Idelle, typically provided as a cream, must be administered using the calibrated applicator provided with the product to ensure the exact dose is delivered. Official administration instructions emphasize using the device as directed; therefore, the dosage form is generally not intended to be altered.

Q: Does Idelle have any long-term monitoring requirements?

A: Yes, periodic medical check-ups and follow-up, often on an annual basis, are recommended while using this medicine. Long-term follow-up typically includes a breast assessment and general medical examination, with emphasis on investigating any unscheduled or prolonged vaginal bleeding.

Q: Is there a generic version of Idelle available?

A: Estriol is a naturally occurring estrogen, and in many global markets, the former branded product has been transitioned or rebranded to the generic name 'Estriol Cream.' Other manufacturers may produce generic versions containing the same active ingredient.

Q: Does Idelle have a warning about driving or operating machinery?

A: Official regulatory documents explicitly state that no effects on the ability to drive or use machines have been observed or are expected with the use of this medicine.

Q: Do you need to avoid sun exposure while using Idelle?

A: While not a universal warning for this specific localized product, other estrogen treatments have listed skin-related side effects, such as patches of discoloration (chloasma), which may sometimes be aggravated by sun exposure.

Q: Are there any official registries or studies about long-term use of Idelle?

A: The official research base is noted to have limited long-term follow-up beyond one year. For ongoing safety, health authorities require continuous reporting of suspected adverse reactions to monitor the benefit/risk balance over time.

Q: Is it possible for Idelle not to work for some people?

A: Official documents acknowledge that studies show what has been observed in large patient groups, but they cannot guarantee that every individual will respond similarly. If a patient does not see expected improvement, consulting with a healthcare provider is recommended.

Q: What is the difference between the different strengths of Idelle?

A: The difference between strengths is the amount of the active ingredient (Estriol) contained in the product. Different strengths are prescribed according to specific treatment phases and may be associated with different administration instructions.

How should Idelle be stored and disposed of?

How to Store and Dispose of Idelle (Official Requirements)

Official regulatory information requires that Idelle be stored at controlled room temperature, typically between 20 C and 25 C, with short excursions permitted up to 30 C. The product must be kept in its original, tightly closed container or packaging to protect it from light and excessive moisture. It is explicitly stated that Idelle must not be frozen or stored above the maximum temperature.

Handling and Disposal

  • Child Safety: Keep this medicine out of the sight and reach of children.
  • Disposal: Unused or expired Idelle must be disposed of according to federal and local regulations. The preferred method is often a drug take-back program or a DEA-authorized collector. Do not discard Idelle by flushing it down a toilet or pouring it down a drain unless specifically advised to do so by an official government guideline for the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Idelle found in:

A-Z Index: